• VERISEQ® Nucleation controls pharmaceutical freeze drying processes •Linde Cryoservices™ program to cryogenically store irreplaceable specimens
MurrayHill & New Providence, New Jersey, U.S., May 21, 2014 -- Linde North America, Inc. will be featuring technologies at BIO International Convention 2014 that will help pharmaceutical manufacturers and biotech companies meet production and environmental requirements. The convention will take place at San Diego Convention Center in San Diego, California June 23-26.
Linde North America is a member of The Linde Group, a world-leading gases and engineering company. The Biotechnology Industry Organization (BIO), founded in 1993, represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the U.S. and in more than 30 other nations.
Within the Bio Partner Pavilion (#4317), Linde representatives will discuss how its technical capabilities can improve the quality, productivity and cost-effectiveness of pharmaceutical, biotech and R&D operations.
Nucleation process improves pharmaceutical freeze drying processes
Featured among the technologies is Linde’s proprietary VERISEQ® Nucleation process that improves control and efficiency of pharmaceutical freeze drying processes. The process controls formation of ice crystals using a sterile cryogenic ice fog resulting in enhanced lyophilization (freeze drying) cycles and improved product quality.
Biologics like proteins, vaccines and other injectables must remain effective from manufacture to patient administration. These substances are expensive, fragile and can lose their efficacy during storage. Lyophilization is a dehydration process for stabilizing these valuable medical substances that is conducted in highly controlled environments and in compliance with strict regulatory guidelines. The temperature at which a vial freezes (ice nucleation temperature) is critical in the process to optimize production times and improve the quality of the final product.
Peter Studer, program manager for VERISEQ® Nucleation, said, “Until now, there has been no real commercially feasible way of achieving uniform ice nucleation, which resulted in prolonged operating cycles, reduced yield and overall uncertainty in scale-up. Our technology provides end users with a new degree of control leading to more robust lyophilization cycles.”
Linde Cryoservices™ program stores irreplaceable specimens
Organizations that need to cryogenically store irreplaceable specimens, such as cord blood, bone marrow, cell lines, blood and organs for transfusion and transplantation, can also meet with Linde representatives to discuss the Linde Cryoservices™ program, specially designed to service all their needs -- from specialized equipment to a complete line of cryopreservation services– virtually anywhere in the U.S.
Don Bongarzone, Cryoservices manager-North America, said, “Linde’s extensive liquid nitrogen supply network, combined with our wealth of experience in the medical/pharmaceutical industry, provides customers with the security of product supply they need and the services that will assure the safe, long-term preservation and distribution of these irreplaceable materials.”
BIO Business Solutions Partner
As a preferred BIO Business Solutions Partner with the BIO, Linde can offer member companies technical know-how, special pricing and rebates on bulk gas products, bulk gas applications, packaged and specialty gases, mini-bulk and related equipment, products and services. The gases covered include cylinder supply for industrial and special gas requirements, on-site generators for nitrogen, oxygen and hydrogen, and liquid supply capabilities for argon, nitrogen, oxygen, carbon dioxide, hydrogen and helium.
In the 2013 financial year, The Linde Group generated revenue of EUR 16.655 bn (USD 23.1 bn), making it the largest gases and engineering company in the world with approximately 63,500 employees working in more than 100 countries worldwide. The strategy of The Linde Group is geared towards long-term profitable growth and focuses on the expansion of its international business with forward-looking products and services. Linde acts responsibly towards its shareholders, business partners, employees, society and the environment – in every one of its business areas, regions and locations across the globe. The company is committed to technologies and products that unite the goals of customer value and sustainable development.
For more information, see The Linde Group online at www.linde.com
Linde corporate communications